Alzheimer‘s Disease
Empowering clinicians to transform Alzheimer’s Disease management.
Be part of it.
Understanding Alzheimer’s with Dr. Ana Franceschi
In this exclusive interview, Dr. Ana Franceschi introduces the latest insights into Alzheimer’s disease, exploring current research, treatments, and the future of neuroimaging. Discover her expert perspective on this complex condition.
The underlying mechanisms behind Alzheimer’s disease are not fully understood. Future advancements in disease management will require innovative technologies that go beyond what is possible today. As one of the leaders in the neuroimaging community, Siemens Healthineers stands together with the brightest minds in academia and industry to make a transformative impact on the management of Alzheimer’s disease.
138 Million People
By 2050, 138 million people may have dementia.1 Screening for Alzheimer’s Disease and differentiating it from other dementia forms will be essential to patient care.
Misdiagnosed
1 in 5 Alzheimer’s cases may be misdiagnosed.2 Alzheimer's disease is often misdiagnosed, possibly causing undue stress for those who don't have the disease but are told they do, and delays in treatment for others.
ARIA Incidence
New disease modifying therapies for Alzheimer's disease have emerged. However, the rate of incidence of their well known side effect, Amyloid Related Imaging Abnormalities (ARIA), was 10-30% in clinical trials.3 Therapeutic monitoring will be key to patient safety.
Thursday, Feb. 27 12:30 (CET), Room 02
Join the symposia at ECR 2025
Dementia Imaging Update: Role of the Radiologist in the Era of Disease-modifying Therapies
Disease Modifying Therapy (DMT)1 for Alzheimer’s Disease
There is now hope for patients, family and friends
The battle against Alzheimer’s disease (AD) has long been one of the most challenging and heart-wrenching. This relentless neurological disorder, marked by cognitive decline and memory loss, has no cure4. However, in recent years new hope has emerged: novel therapies, so called Disease-Modifying Therapies (DMT)5, which claim to slow progression of this devastating disease6 , are entering the market.
These new DMTs, while promising, require careful consideration to:
- Find the patients early enough in the disease progression
- Monitor these patients against adverse effects once treatment begins
Numerous tests are used to diagnose Alzheimer’s disease, from laboratory tests to diagnostic neuroimaging.7 Siemens Healthineers offers a comprehensive portfolio to help healthcare providers transform their management of Alzheimer’s disease patients.
How DMT2 works
Amyloid beta protein accumulates around brain neurons in Alzheimer’s
DMT antibody binds to amyloid beta protein
Antibody attracts immune cells to break down the protein
Less amyloid beta protein around the neuron
PET/CT and PET/MR
Our BIOGRAPH family of PET/CT and PET/MR scanners are crucial in evaluating amyloid plaques burden in the brain. PETNET Solutions provides specialized tracers that bind to amyloid plaques, confirming their presence. This confirmation helps physicians to identify Alzheimer's at an early stage. As visual assessment alone can be challenging for interpreting amyloid clinical cases syngo.via MI Neurology offers a powerful software with Cortical Analysis that encompasses SUVr and Centiloid to aid physicians in evaluating amyloid plaques.
MRI
MRI plays a key role in managing patients along the Alzheimer’s disease pathway. New pharmaceutical treatments require MRI scans at defined timepoints to follow-up for signs of ARIA (amyloid related imaging abnormalities), known side effects associated with these new treatments.1,8 Every MAGNETOM scanner in our MR portfolio is equipped, out-of-the-box, to handle the scan requirements mandated by these novel therapies. AI-powered 1,8 technologies such as myExam Brain Assist, Deep Resolve Boost, Sharp and Swift Brain is supposed to make sure that the scans are fast, automated, and reproducible. AI-Rad Companion Brain MR automates the visualization of anatomy and abnormalities in the brain.
Are you interested?
Share
Do you find this page interesting? Share the information with peers.
1World Alzheimer Report 2024
2https://www.cbsnews.com/news/alzheimers-cases-misdiagnosed-men-women/
3https://pubs.rsna.org/doi/epdf/10.1148/rg.230205
4Abubakar MB, Sanusi KO, Ugusman A, Mohamed W, Kamal H, Ibrahim NH, Khoo CS, Kumar J. Alzheimer's Disease: An Update and Insights Into Pathophysiology. Front Aging Neurosci. 2022 Mar 30;14:742408. doi: 10.3389/fnagi.2022.742408. PMID: 35431894; PMCID: PMC9006951.
5Disease-Modifying Therapy (DMT) in Alzheimer’s disease comes with risks. Please refer to the specific DMT's prescribing information for side effects, contraindications, and risks.
6Shi, Mingchao, Chu, Fengna, Zhu, Feiqi, Zhu, Jie. Impact of Anti-amyloid-β Monoclonal Antibodies on the Pathology and Clinical Profile of Alzheimer’s disease: A Focus on Aducanumab and Lecanemab https://doi.org/10.3389/fnagi.2022.870517
7Marcus C, Mena E, Subramaniam RM. Brain PET in the diagnosis of Alzheimer's disease. Clin Nucl Med. 2014 Oct;39(10):e413-22; quiz e423-6. doi: 10.1097/RLU.0000000000000547. PMID: 25199063; PMCID: PMC4332800.
8https://www.thelancet.com/lancet/visualisations/gbd-compare